We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering RNAi Platform
News

RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering RNAi Platform

RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering RNAi Platform
News

RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering RNAi Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering RNAi Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RXi Pharmaceuticals Corporation has announced that it has received the Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA®).

The patent, titled "Reduced Size Self-Delivering RNAi Compounds", broadly covers both the composition and methods of use of RXi's self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029.

This core patent, within RXi's intellectual property portfolio, is the foundation for RXI's self-delivering platform. The patent broadly protects RXi's sd‑rxRNA technology, which facilitates the delivery of RNAi compounds to tissues and cells of interest in the absence of a delivery vehicle.

sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.

"We are pleased to have our novel technology recognized by the United States Patent and Trademark Office," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This key patent is what differentiates RXi's technology platform from the competition. It provides us with a powerful advantage to deliver our RNAi compounds without delivery vehicles, which are commonly used with the other siRNA compounds in clinical development. The use of our proprietary sd‑rxRNA technology platform may lead to improved tolerability and thereby potentially broadening of the therapeutic window for these compounds."

Advertisement